TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3596336

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg nocte
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ranitidine 2 X 150 mg per day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30526588

Group type: EXPERIMENTAL
Intervention: Two rounds of mass drug administration (MDA) with dihydroartemisinin‐piperaquine and single low‐dose primaquine, administered 4 weeks apart in May‐June 2016.
Number of subjects: 21000

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 21000
Study: 26583280

Group type: EXPERIMENTAL
Intervention: Glass-modified Jones tube injector (Gunther Weiss Scientific Glass)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Closed-system intraocular lens injector (Viscoject 2.2; Medicel)
Number of subjects: 18
Study: 24590636

Group type: EXPERIMENTAL
Intervention: Yoga (YG)
Number of subjects: 163
Study: 23243978

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU; glutaraldehyde/HEMA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLA; water)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BisBlock (BIS; oxalate)
Number of subjects: 50
Study: 21143839

Group type: EXPERIMENTAL
Intervention: rs1044925 polymorphism in the ACAT-1 gene in Bai Ku Yao females
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: C allele carriers in Bai Ku Yao
Number of subjects: 1250

Group type: COMPARATOR
Intervention: rs1044925 polymorphism in the ACAT-1 gene in Han population
Number of subjects: 1250
Study: 18402714

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 15618781

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 32
Study: 11875582

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (10 mmol) infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 22
Study: 10448830

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 23‐35 mg/kg/day, t.i.d.
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 7799699

Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2149388

Group type: EXPERIMENTAL
Intervention: cilazapril (2.5 to 5.0 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: hydrochlorothiazide (25 to 50 mg)
Number of subjects: 30
Study: 364285

Group type: EXPERIMENTAL
Intervention: Combination of vincristine and prednisone with streptonigrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of vincristine and prednisone with cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remission maintenance with cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remission maintenance with methotrexate
Number of subjects: 0
Study: 30554751

Group type: EXPERIMENTAL
Intervention: Home-based screening for abnormal vaginal flora and urinary tract infections; treatment with oral clindamycin (300 mg twice daily for 5 days) for abnormal vaginal flora and cefixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg twice daily for 7 days) for urinary tract infections.
Number of subjects: 9712

Group type: COMPARATOR
Intervention: Control group received standard antenatal and postnatal care without the specific screening and treatment for infections.
Number of subjects: 9712

Group type: EXPERIMENTAL
Intervention: Home-based screening for abnormal vaginal flora and urinary tract infections.
Number of subjects: 9712

Group type: EXPERIMENTAL
Intervention: Treatment of abnormal vaginal flora and urinary tract infections in the intervention group.
Number of subjects: 9712
Study: 28072802

Group type: EXPERIMENTAL
Intervention: 10% sodium chloride solution added to lidocaine, triamcinolone, and hyaluronidase (hypertonic group)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (conventional transforaminal epidural steroid injections)
Number of subjects: 246
Study: 26026527

Group type: EXPERIMENTAL
Intervention: Automatic real-time evaluation of red blood cell elasticity using optical tweezers
Number of subjects: 150

Group type: COMPARATOR
Intervention: Expert measurements of RBC elasticity
Number of subjects: 150
Study: 23896831

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to 32-33°C for 48 hours)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Controlled normothermia (as control)
Number of subjects: 19
Study: 20642487

Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 2084

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2084
Study: 19270861

Group type: EXPERIMENTAL
Intervention: Warmed contrast material (Omnipaque [Iohexol] 350 mg I/mL at 37 degrees C)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Room temperature contrast material (Omnipaque [Iohexol] 350 mg I/mL at 24 degrees C)
Number of subjects: 64
Study: 17699431

Group type: EXPERIMENTAL
Intervention: Low-sodium (Na)/high-potassium (K) diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-Na/low-K diet
Number of subjects: 40
Study: 15465995

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-dose omega-3 fatty acids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (bipolar subjects without omega-3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (subjects without bipolar disorder)
Number of subjects: 12
Study: 11465517

Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment after a 4-day washout period
Number of subjects: 103

Group type: COMPARATOR
Intervention: Immediate switch from SSRI to mirtazapine
Number of subjects: 103
Study: 9716041

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 144
Study: 7991118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 2738209

Group type: EXPERIMENTAL
Intervention: Instructions to monitor labor contractions and attendance at LaMaze classes (Study 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Attendance at LaMaze classes (Study 2)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 77
Study: 182347

Group type: EXPERIMENTAL
Intervention: Estrogen treatments (Premarin, Provera, Provera and diethylstilbestrol, diethylstilbestrol alone)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Diethylstilbestrol or placebo
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Initial triglyceride levels
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Initial cholesterol levels
Number of subjects: 1093
Study: 31318743

Group type: EXPERIMENTAL
Intervention: Orthosis combined with exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthotic intervention only
Number of subjects: 0
Study: 28830796

Group type: EXPERIMENTAL
Intervention: Sorafenib with capecitabine
Number of subjects: 537

Group type: COMPARATOR
Intervention: Capecitabine with placebo
Number of subjects: 537
Study: 26537725

Group type: EXPERIMENTAL
Intervention: New dental nurse-led service using a brief negotiated interview based on motivational interviewing, delivered between enrollment and 6 weeks post-extraction.
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard care (treatment as usual)
Number of subjects: 224
Study: 23922146

Group type: EXPERIMENTAL
Intervention: TEVAR
Number of subjects: 140

Group type: COMPARATOR
Intervention: Optimal medical treatment alone
Number of subjects: 140
Study: 21536812

Group type: EXPERIMENTAL
Intervention: Guaiac-based FOB test (Hemoccult) with dietary restriction and three test cards for six consecutive samples
Number of subjects: 74592

Group type: EXPERIMENTAL
Intervention: Guaiac-based FOB test (Hemoccult)
Number of subjects: 74592
Study: 19657295

Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg BW caffeine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3 mg.kg BW caffeine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17244923

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg x kg(‐1) before heparin and before protamine injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Autotransfusion (1‐2 units of autologous blood after cardiopulmonary bypass)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Autotransfusion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tranexamic acid and autotransfusion
Number of subjects: 200
Study: 14746622

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% used twice daily
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Topical corticosteroids (reactive treatment)
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Placebo (in short-term studies)
Number of subjects: 1550
Study: 11719310

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no nocturnal oxygen therapy)
Number of subjects: 23
Study: 9207636

Group type: EXPERIMENTAL
Intervention: abciximab (c7E3) bolus immediately before the intervention
Number of subjects: 489
Study: 7535080

Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen with rG-CSF 5 micrograms/kg/day for 4 consecutive days starting on day 2 of every week
Number of subjects: 67

Group type: COMPARATOR
Intervention: P-VEBEC regimen without rG-CSF
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients with RDI > 80%
Number of subjects: 67
Study: 3310952

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 29370014

Group type: EXPERIMENTAL
Intervention: In-person mindfulness-based resilience training (MBRT) for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered resiliency-based intervention for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study: 27748432

Group type: EXPERIMENTAL
Intervention: FLIPUS+diclofenac sodium
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham FLIPUS+diclofenac sodium
Number of subjects: 106
Study: 25633497

Group type: EXPERIMENTAL
Intervention: Oral reduced L-glutathione (GSH) 65 mg · kg(‐1) · day(‐1) divided into 3 doses per day for 6 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral reduced L-glutathione (GSH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (calcium citrate)
Number of subjects: 44
Study: 24346292

Group type: EXPERIMENTAL
Intervention: PNF combined with ERB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 20184615

Group type: EXPERIMENTAL
Intervention: Psychotropic medication (mostly pimozide)
Number of subjects: 182
Study: 18568349

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 60
Study: 16983923

Group type: COMPARATOR
Intervention: Amiodarone (group A, n=14)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Irbesartan and amiodarone (group B, n=15)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: WG plus irbesartan and amiodarone (group C, n=12)
Number of subjects: 41
Study: 14570168

Group type: EXPERIMENTAL
Intervention: H2S olfactory stimuli
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CO2 trigeminal stimuli
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral temperature
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sleepiness
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Blood pressure, heart rate, nasal volume
Number of subjects: 5
Study: 15353387

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10199876

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) - 50 microgram bolus, then 50 ng.kg‐1.min‐1
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) - 8 mg/min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) and Nitroglycerin (NTG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -6 mm Hg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -12 mm Hg
Number of subjects: 15
Study: 7774991

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoprolol (40 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2213115

Group type: EXPERIMENTAL
Intervention: Prognostic index derived from multivariate analysis of prognostic factors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic index groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent MRC trial verification
Number of subjects: 0
Study: 356763

Group type: EXPERIMENTAL
Intervention: Intra-articular methotrexate (MTX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study: 31420467

Group type: EXPERIMENTAL
Intervention: Carboplatin/pemetrexed plus apatorsen
Number of subjects: 155

Group type: COMPARATOR
Intervention: Carboplatin/pemetrexed plus placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Apatorsen in patients with high serum levels of Hsp27
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo in patients with high serum levels of Hsp27
Number of subjects: 155
Study: 28452623

Group type: EXPERIMENTAL
Intervention: OFD+PRF
Number of subjects: 26

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 26
Study: 25803679

Group type: EXPERIMENTAL
Intervention: 10 J/cm² IPL treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 13 J/cm² IPL treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both 10J and 13J IPL treatment
Number of subjects: 20
Study: 24105697

Group type: EXPERIMENTAL
Intervention: Magnesium (50 mg/kg bolus followed by 50 mg/kg infusion for 3 hours)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo (bolus and infusion)
Number of subjects: 389
Study: 21212307

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 759) performed 4 strengthening and 4 stretching exercises during supervised physical training lessons (7 per week).
Number of subjects: 770

Group type: COMPARATOR
Intervention: Control group (n = 743) followed existing training syllabus warm-up exercises.
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 759) performed exercises.
Number of subjects: 770
Study: 19204597

Group type: EXPERIMENTAL
Intervention: 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 8 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 12 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310

Group type: COMPARATOR
Intervention: 8 kcal x kg(‐1) x wk(‐1) vs 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310

Group type: COMPARATOR
Intervention: 12 kcal x kg(‐1) x wk(‐1) vs 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study: 16881426

Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 15682844

Group type: EXPERIMENTAL
Intervention: Scatter and cross-talk correction imaging protocol
Number of subjects: 14
Study: 11412218

Group type: EXPERIMENTAL
Intervention: Consumption of cooked tomatoes
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Increased alcohol intake
Number of subjects: 112

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 112

Group type: COMPARATOR
Intervention: Coffee consumption
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Age >75 years
Number of subjects: 112
Study: 9402327

Group type: EXPERIMENTAL
Intervention: Smooth muscle tumors (leiomyosarcomas) in children with AIDS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EBV infection in smooth muscle cells
Number of subjects: 8
Study: 8425280

Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study: 29307259

Group type: EXPERIMENTAL
Intervention: Workplace social capital in provider burnout
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cohesive work teams
Number of subjects: 40
Study: 27461675

Group type: EXPERIMENTAL
Intervention: Group A: Paclitaxel 175 mg/m² on day 1 and Carboplatin 450 mg on day 2 (PC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B: Docetaxel and Cisplatin 75 mg/m² each on day 1 and Ifosfamide 2 g/m² on day 1-3 along with Mesna (docetaxel-ifosfamide-cisplatin)
Number of subjects: 60
Study: 25131839

Group type: EXPERIMENTAL
Intervention: Curcumin extract (630mg thrice daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (thrice daily)
Number of subjects: 65
Study: 23303874

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19816719

Group type: EXPERIMENTAL
Intervention: Thin copper foils of different thickness (5-200 µm) inserted between the teeth.
Number of subjects: 68
Study: 20633377

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS (1000 pulses per day, 20,000 total)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 1 Hz rTMS (100 pulses per day, 2000 total)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 51
Study: 15678413

Group type: EXPERIMENTAL
Intervention: Ordered categorical doses of antidepressants
Number of subjects: 250
Study: 12670818

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg.kg(‐1) iv (maximum dose 8 mg)
Number of subjects: 120
Study: 11105399

Group type: EXPERIMENTAL
Intervention: Computer-mediated telecommunications system for family caregivers
Number of subjects: 0
Study: 8669074

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 198
Study: 1482735

Group type: EXPERIMENTAL
Intervention: 1 MAC halothane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.3 MAC isoflurane
Number of subjects: 40
Study: 6374278

Group type: EXPERIMENTAL
Intervention: LMWH 1 (2,500 APTT units b.i.d.)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: LMWH 2 (5,000 APTT units b.i.d.)
Number of subjects: 126

Group type: COMPARATOR
Intervention: UFH (5,000 APTT units b.i.d.)
Number of subjects: 126
Study: 31347292

Group type: EXPERIMENTAL
Intervention: Tarextumab with nab-paclitaxel and gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and gemcitabine
Number of subjects: 0
Study: 30128538

Group type: EXPERIMENTAL
Intervention: A‐tDCS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 74

Group type: COMPARATOR
Intervention: A‐tDCS vs Sham tDCS
Number of subjects: 74
Study: 27435791

Group type: EXPERIMENTAL
Intervention: nifuratel-500 (500 mg nifuratel, intravaginal, 10 days)
Number of subjects: 142

Group type: COMPARATOR
Intervention: nifuratel-250 (250 mg nifuratel, intravaginal, 10 days)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: nifuratel-500
Number of subjects: 142
Study: 24394884

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (50 mg)
Number of subjects: 200
Study: 23018438

Group type: EXPERIMENTAL
Intervention: RAL
Number of subjects: 233
Study: 20478753

Group type: EXPERIMENTAL
Intervention: Intervention group (BTS collaborative methodology)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 10
Study: 17562667

Group type: EXPERIMENTAL
Intervention: Ischaemic group (exercise training at a target intensity that induced myocardial ischaemia)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (exercise training adhering to current guidelines)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ischaemic group
Number of subjects: 22
Study: 16095462

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 10 mg/h + morphine 0.16 mg/h (Group L)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 16 mg/h + morphine 0.16 mg/h (Group H)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo PCA morphine (Group PL)
Number of subjects: 45
Study: 11861242

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10459904

Group type: EXPERIMENTAL
Intervention: Immediate surgery (ventilation-tube insertion) within 6 weeks (n=92)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Watchful waiting for 9 months (n=90)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both groups after 18 months
Number of subjects: 186
Study: 7791061

Group type: EXPERIMENTAL
Intervention: Topical 1% apraclonidine, one drop before and after surgery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sustained-release acetazolamide, 500 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 54